0人評分過此書

Fast Facts: Myeloproliferative Neoplasms

出版社
出版日期
2019/02/11
閱讀格式
EPUB
書籍分類
學科分類
ISBN
9781910797808

本館館藏

借閱規則
當前可使用人數 30
借閱天數 14
線上看 0
借閱中 0
選擇分享方式

推薦本館採購書籍

您可以將喜歡的電子書推薦給圖書館,圖書館會參考讀者意見進行採購

讀者資料
圖書館
* 姓名
* 身分
系所
* E-mail
※ 我們會寄送一份副本至您填寫的Email中
電話
※ 電話格式為 區碼+電話號碼(ex. 0229235151)/ 手機格式為 0900111111
* 請輸入驗證碼
Presentation of the myeloproliferative neoplasms (MPNs) varies widely, and correct diagnosis and management can be challenging, and is becoming more complex as understanding of the underlying molecular basis for these disorders emerges. Appropriate management is increasingly informed by accurate risk stratification founded on understanding of cytogenetic and molecular markers, as well as the clinical presentation. 'Fast Facts: myeloproliferative neoplasms' focuses on the three most common chronic MPNs: ‧ Essential thrombocythemia (ET) – characterized by increased platelet count ‧ Polycythemia vera (PV) – characterized by excessive production of red blood cells ‧ Primary myelofibrosis – a more severe and heterogenous disorder that may overlap with ET and PV but is commonly associated with anemia. Written by two leading experts in the field, Fast Facts: myeloproliferative neoplasms provides concise, up-to-date and practical guidance on the accurate diagnosis, risk stratification and management of these MPNs. It also provides key insights into our growing understanding of the underlying molecular and genetic basis of these disorders, and how this is informing risk stratification and management strategies. This concise handbook will be invaluable to clinicians, medical students, nurses, pharmacists and scientists in understanding and overcoming the everyday and rarer challenges associated with MPN.
  • Cover
  • Title Page
  • Copyright
  • Contents
  • List of abbreviations
  • Introduction
  • 1 Pathogenesis and etiology
    • Genetic basis
    • Clonal hematopoiesis of indeterminate potential (CHIP)
    • Inflammation
    • Other environmental factors
  • 2 Epidemiology
    • Incidence
    • Prevalence
    • Survival
    • Risk factors
  • 3 Diagnosis and disease burden
    • Clinical presentation
    • Diagnosis
    • Diagnosis of essential thrombocythemia
    • Diagnosis of polycythemia vera
    • Diagnosis of primary myelofibrosis
    • Disease burden
    • Risk stratification
  • 4 Management of essential thrombocythemia
    • Aims of treatment
    • Stratification of treatment according to risk
    • First-line treatment
    • Second-line treatment
    • Management of extreme thrombocytosis
    • Recognizing treatment failure
  • 5 Management of polycythemia vera
    • Aims of treatment
    • Current treatment options
    • Stratification of treatment according to risk
    • Phlebotomy
    • Antiplatelet therapy
    • Cytoreductive therapy
    • Janus kinase inhibitors
    • Managing the risk of transformation to myelofibrosis/blast phase
    • Criteria for treatment response
  • 6 Management of myelofibrosis
    • Aims of treatment
    • Risk stratification
    • Therapeutic options
    • Janus kinase inhibitors
    • Stem cell transplantation
    • Supportive therapy
    • Treatment of blast phase myelofibrosis
    • Monitoring treatment
  • 7 New treatments for myeloproliferative neoplasms
    • JAK inhibitors
    • Ropeginterferon
    • Other therapeutic targets
    • Erythropoiesis inhibitor blockers
    • Combination therapy
  • 8 Management of specific situations
    • MPNs in women: influence of sex on phenotype
    • MPNs in children
    • Splanchnic vein thrombosis
    • Elective surgery
  • 9 Management of myeloproliferative neoplasm blast phase
    • Diagnosis
    • Treatment
  • Useful resources
  • Index
  • 出版地 德國
  • 語言 德文

評分與評論

請登入後再留言與評分
幫助
您好,請問需要甚麼幫助呢?
使用指南

客服專線:0800-000-747

服務時間:週一至週五 AM 09:00~PM 06:00

loading